KBC Group NV Decreases Position in Henry Schein, Inc. (NASDAQ:HSIC)

KBC Group NV cut its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 49.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 225,371 shares of the company’s stock after selling 219,241 shares during the period. KBC Group NV’s holdings in Henry Schein were worth $16,429,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Swedbank AB purchased a new position in shares of Henry Schein during the first quarter worth approximately $215,998,000. Thompson Siegel & Walmsley LLC purchased a new stake in Henry Schein during the second quarter valued at approximately $46,683,000. SG Americas Securities LLC boosted its position in shares of Henry Schein by 1,622.3% in the 3rd quarter. SG Americas Securities LLC now owns 458,828 shares of the company’s stock worth $33,449,000 after purchasing an additional 432,187 shares in the last quarter. Private Management Group Inc. acquired a new stake in Henry Schein in the third quarter worth about $24,176,000. Finally, Magnetar Financial LLC grew its position in Henry Schein by 229.9% during the 1st quarter. Magnetar Financial LLC now owns 386,458 shares of the company’s stock worth $29,185,000 after purchasing an additional 269,330 shares during the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Price Performance

HSIC opened at $68.76 on Friday. The stock’s 50-day moving average price is $70.30 and its 200 day moving average price is $69.57. Henry Schein, Inc. has a 12-month low of $63.67 and a 12-month high of $82.63. The firm has a market cap of $8.57 billion, a price-to-earnings ratio of 28.30, a PEG ratio of 1.94 and a beta of 0.87. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $1.22 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.05. The firm had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.24 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The business’s quarterly revenue was up .4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.32 earnings per share. As a group, sell-side analysts expect that Henry Schein, Inc. will post 4.78 earnings per share for the current year.

Insiders Place Their Bets

In other Henry Schein news, SVP Lorelei Mcglynn sold 21,035 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $69.30, for a total value of $1,457,725.50. Following the transaction, the senior vice president now directly owns 71,833 shares in the company, valued at $4,978,026.90. This represents a 22.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.14% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

HSIC has been the topic of a number of research reports. UBS Group cut their price objective on Henry Schein from $75.00 to $72.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. StockNews.com upgraded shares of Henry Schein from a “sell” rating to a “hold” rating in a research report on Thursday, November 7th. Robert W. Baird dropped their price target on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. JPMorgan Chase & Co. cut their price objective on Henry Schein from $88.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Finally, Barrington Research reiterated an “outperform” rating and issued a $82.00 target price on shares of Henry Schein in a research report on Wednesday, November 6th. Six equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $78.89.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.